Mixed Connective Tissue Disease: Treating the Flaring Organ Without Neglecting the Others
A single patient whose mixed connective tissue disease is shifting from joints to muscle, with a new pulmonary-pressure finding riding alongside. No trial exists to say which organ's playbook should lead.
Ana N., 32, is raising two children under five and works part-time from home around their schedules. She was diagnosed two years ago with anti-U1RNP-positive mixed connective tissue disease after presenting with puffy hands, Raynaud's, and an inflammatory polyarthritis that has been reasonably controlled since on hydroxychloroquine alone — light treatment, in retrospect, for two years of active joint disease, though it had seemed adequate at the time. Over the past four months a new feature has taken over: proximal muscle weakness with a rising creatine kinase, a genuine myositis flare, while her skin and Raynaud's have stayed stable and her mild esophageal dysmotility hasn't changed.
A recent echocardiogram, obtained as part of the same visit, incidentally found her estimated pulmonary artery pressure mildly elevated — an estimate, not a measurement, and one that echocardiography is known to get wrong in both directions, which is precisely why it cannot be either acted on or dismissed as it stands. It is also not something to set aside, because pulmonary arterial hypertension is not merely a complication of MCTD but its characteristic way of killing people: in Hajas and colleagues' 280-patient Hungarian cohort, PAH accounted for nine of the twenty-two deaths, more than any other single cause. Her mild esophageal dysmotility, stable and easy to file as background, belongs to the same scleroderma-like axis of the disease as that pressure reading, and it is the one feature of hers already pointing down that road. No randomized trial exists for myositis treatment specifically within MCTD, so any drug choice here is an extrapolation from idiopathic inflammatory myopathy management, not a population-matched answer — and that same extrapolation gap raises the harder question of whether treating the newly loud organ risks quietly under-treating the joint disease that two years of hydroxychloroquine monotherapy may never have fully controlled in the first place.
In clinic, a myositis flare and an incidental pulmonary-pressure finding
Her CK is rising and she has real, measurable weakness — that's the acute priority today. There's no MCTD-specific myositis trial to guide us, so I'm extrapolating from idiopathic inflammatory myopathy management: prednisone at 1mg/kg with a taper, plus azathioprine as the steroid-sparing agent. Azathioprine specifically because she's told us she may want another pregnancy, and it has the cleaner track record for that.
The myositis needs treating now — I'm not disputing that.
But two years of active polyarthritis controlled on hydroxychloroquine alone is a light regimen by ordinary arthritis standards. I'd use methotrexate instead of azathioprine specifically because it has real, if less-studied, efficacy in both inflammatory arthritis and myositis — it could address the joint disease that may never have been adequately treated, rather than escalating for the muscle flare while leaving the joints where they've been for two years.
I'm not going to weigh in on azathioprine versus methotrexate. But the elevated pulmonary artery pressure on her echo needs a right-heart catheterization to confirm and stage before anyone considers a pulmonary vasodilator, and that needs to happen now — in Hajas's 280-patient MCTD cohort, PAH was the single largest cause of death, nine of twenty-two, and neither prednisone nor methotrexate meaningfully touches that risk. An echo estimate is also exactly the kind of number that gets quietly downgraded to 'mild' and never revisited.
Whatever the two of you decide about her joints and muscles, this axis runs in parallel, not behind it.
Agreed: prednisone taper for the acute myositis flare, methotrexate — not azathioprine — added as the steroid-sparing agent, contingent on confirming reliable contraception before the first dose given methotrexate's teratogenicity; right-heart catheterization ordered urgently, in parallel, to characterize the pulmonary-pressure finding before any vasodilator decision.
The myositis-focused rheumatologist's preference for azathioprine, raised specifically for its cleaner compatibility with an earlier future pregnancy, was set aside once the group agreed on a concrete plan to revisit the choice directly if she reports wanting to conceive again within the next year — a genuine future contingency, not a live disagreement about today's regimen.